\u2022\tRegulatory requirement for drug development and approval in United States: review

负责人：

关键词：

111701 Aboriginal and Torres Strait Islander Health 111001 Aged Care Nursing 111702 Aged Health Care 110301 Anaesthesiology 110901 Autonomic Nervous System 111501 Basic Pharmacology Biomarkers 110601 Biomechanics 111201 Cancer Cell Biology 111202 Cancer Diagnosis

DOI：

doi:10.6084/m9.figshare.3381274.v1

摘要：

drug, the submission of supplemental NDAs for labeling changes, and the role and responsibility of advisory committees are addressed. Along with this a brief description